z-logo
open-access-imgOpen Access
Bilateral renal infarction with COVID-19 pneumonia: a case report
Author(s) -
Kundan Jana,
Kalyana C. Janga,
Sheldon Greenberg,
Kamlesh Kumar
Publication year - 2021
Publication title -
oxford medical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.169
H-Index - 9
ISSN - 2053-8855
DOI - 10.1093/omcr/omab121
Subject(s) - medicine , infarction , myocardial infarction , pneumonia , coagulopathy , pulmonary infarction , intensive care medicine , acute kidney injury , cardiology , incidence (geometry) , covid-19 , apixaban , kidney disease , disease , pulmonary embolism , atrial fibrillation , infectious disease (medical specialty) , rivaroxaban , warfarin , physics , optics
Acute renal infarction is a rare and often underdiagnosed condition with estimated incidence of 0.5–1.5%. Coronavirus disease 2019 (COVID-19) has been shown to cause a hypercoagulable state in patients leading to arterial and venous thromboembolism. Renal infarction as a consequence of COVID-associated coagulopathy has been reported, sometimes resulting in acute kidney injury. Most of the patients so far reported had other existing comorbidities and risk factors that compounded the risk of precipitating an infarction. Here, we present a 37-year-old, the youngest patient reported so far, with no pre-existing comorbidities or risk factors, who developed bilateral renal infarction with COVID-19 pneumonia. The patient was treated with anticoagulation for renal infarction and discharged on apixaban. Anticoagulation is an important part of current treatment strategies for COVID-19 pneumonia and should extend beyond the acute phase of the disease to prevent long-term sequelae, especially in young patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom